Jianxin Chen, ZhenGe Biotech chairman and CEO
January 11, 2022 10:33 AM EST
Financing
Manufacturing

Low-pro­file Shang­hai-based CD­MO se­cures high pro­file in­vestors for 9-dig­it Se­ries C

Paul Schloesser

Associate Editor

In a bid to ex­pand R&D and man­u­fac­tur­ing ca­pa­bil­i­ties, Shang­hai-based ZhenGe Biotech net­ted a $100 mil­lion Se­ries C Tues­day.

With of­fices in Shang­hai and the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Sanofi re­veals pos­i­tive da­ta for BTK in­hibitor from $3.7B Prin­cip­ia takeover

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times